If your recovery stopped keeping up with your training, you have probably run into two options that sound almost identical: BPC-157 on its own, and the BPC-157 + TB-500 combo. The honest starting point is that BPC-157 and the BPC-157 + TB-500 combo are research peptides, not FDA-approved products, and which one fits you is a decision a licensed provider makes after reviewing your intake, not a box you pick yourself.
Here is the question most people are actually asking. Recovery is slower than it used to be. Something nagging is not settling down. You went looking, you found BPC-157, and then you found the combo, and now you are stuck on which one to start with.
This is a decision guide, not a sales pitch. We will keep the mechanisms straight, tell you where TB-500 honestly stands with the FDA right now, and be direct about who makes the call. No outcome promises, no healing timelines, no hype.
First, What You Are Actually Deciding
The "which one" framing feels like a shopping choice. It is not.
Both of these are compounded research peptides. They are not FDA-approved for any use. In the United States they are available only after a licensed provider reviews your history and decides a prescription is appropriate, and only when a licensed pharmacy can lawfully compound what was prescribed. Approval is not automatic, and some people will not be approved.
So the real decision is not "BPC-157 or the combo." It is "what is currently available, and what does a provider think fits me." Everything below is meant to help you walk into that evaluation informed, not to hand you a protocol.
What BPC-157 Is
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids based on a partial sequence identified in human gastric juice. It is studied in preclinical models, meaning animal and cell-culture work, for its role in tissue-repair signaling and angiogenesis, the formation of new blood vessels.
Of the two peptides in this comparison, BPC-157 has the deeper preclinical literature and the more straightforward regulatory position. It is the more common place to start a conversation, precisely because it is the simpler one. For a fuller walkthrough of the peptide itself, see the TelosRX BPC-157 patient guide.
A few things worth being precise about:
- It is not FDA-approved for any human use.
- Where available, it is a compounded preparation, dispensed by a licensed pharmacy under a valid prescription after provider evaluation.
- The research maps a plausible biological mechanism. It does not prove a specific result in humans, and human data remains limited.
What TB-500 Would Add
TB-500 is the research name commonly attached to a fragment of thymosin beta-4, a peptide found in nearly all mammalian cells. It is studied for a different mechanism than BPC-157: actin regulation, which relates to the cytoskeletal protein involved in cell structure and movement, and cell migration.
The logic behind pairing the two is that they are studied for complementary signals rather than the same one. That is the entire appeal of the combo. For more on the peptide on its own, see the TelosRX TB-500 research overview.
But before you treat "add TB-500" as a simple upgrade, you need the part most write-ups skip.
The Honest Part: Where TB-500 Actually Stands Right Now
This is the piece that changes the whole decision.
In late 2023, the FDA placed TB-500 (thymosin beta-4) on its bulk drug substances Category 2 list. Category 2 covers substances the FDA has flagged for significant safety questions or insufficient evidence to support compounding for human use. Under that classification, licensed compounding pharmacies are currently prohibited from preparing or dispensing TB-500 for human administration.
In plain terms: the combo page exists, but TB-500 is not something a compliant pharmacy can simply hand you today. Any source claiming otherwise is operating outside the lines that legitimate, licensed pharmacies follow, and we are not going to pretend the combo is freely available when it is not.
This status is not written in stone. Bulk drug substance classifications get reviewed over time by the FDA and the Pharmacy Compounding Advisory Committee (PCAC). A PCAC review sits on the calendar for July 23 and 24, 2026, the same window this is being written. Committee reviews can influence which substances pharmacies may compound. We are not going to predict what this one decides. What we can tell you is that the picture is evolving, and what is offerable can change with it.
For the fuller regulatory background and how the two peptides sit in different positions, the TelosRX explainer on the "Wolverine stack" nickname covers it in depth.
So, Which One? A Simple Way to Think About It
Here is the framework we would actually use. Start with what you are trying to do, then let the regulatory reality and a provider narrow it down.
| If this sounds like you | Where the conversation usually starts |
|---|---|
| You want to keep it simple and begin with one well-studied option | BPC-157 on its own is the more straightforward starting point, and it carries the deeper preclinical literature of the two. |
| You have read about the combo and want a provider to weigh it | The BPC-157 + TB-500 page is where that conversation happens. What is actually offerable depends on current regulatory status, including the TB-500 restriction above. |
| You are a tested competitive athlete | Both are treated as prohibited substances under WADA and USADA rules (S0, non-approved substances). This is not the path for you while you are subject to testing. Check with your sport's anti-doping authority. |
| You want a definitive protocol handed to you | That is not something we, or any compliant service, can do. A licensed provider decides after intake, and some people will not be approved. |
Notice what the table does not say. It does not tell you the combo is "better," or that stacking is an upgrade, or that either one will do anything specific for you. The most useful default, when in doubt, is usually the simpler starting point, then a provider's judgment on top of it. The rest depends on you, and on what can lawfully be compounded when you actually go through the process.
How It Works at TelosRX
The evaluation is asynchronous, so there is no waiting room and no scheduled call. Here is the shape of it:
- You complete a detailed intake covering your health history, current medications, and what you are trying to address.
- A licensed US provider reviews it and decides whether a prescription is appropriate, whether more information is needed, or whether the answer is no.
- If something is approved, it is compounded by a licensed US pharmacy under federal and state compounding regulations, and only for what can lawfully be prepared at that time.
- Care does not end at the prescription. You have an ongoing line to check in as things change.
You can review the two research pages before you start: BPC-157 and BPC-157 + TB-500. Neither page is a promise of approval. Both lead to the same place, an evaluation that decides what, if anything, fits you.
Pricing, so you are not guessing: BPC-157 on its own is as low as $116 per month, and BPC-157 + TB-500 is as low as $133 per month. Both figures are program pricing if a provider approves you, not a quote. What can actually be dispensed still depends on provider judgment and on the compounding status described above.
Frequently Asked Questions
Should I start with BPC-157 alone or the BPC-157 + TB-500 combo?
There is no one-size answer, and that decision belongs to a licensed provider after reviewing your intake. As a general orientation, BPC-157 on its own is the simpler, more heavily studied starting point of the two. The combo adds TB-500, which is studied for a different mechanism but currently sits under an FDA compounding restriction. What actually fits you, and what can lawfully be compounded, is determined during your evaluation.
Can I actually get TB-500 right now?
Not for human use through a compliant pharmacy. The FDA placed TB-500 (thymosin beta-4) on its Category 2 bulk drug substances list in late 2023, which currently prohibits licensed compounding pharmacies from preparing or dispensing it for human administration. This is a regulatory restriction, not a supply problem, and it applies regardless of which telehealth service is asked. The status can change as FDA and PCAC review continues.
Is the BPC-157 + TB-500 combo FDA-approved?
No. Neither BPC-157 nor TB-500 is FDA-approved for any human use. Where a compliant compounding path exists, it operates under federal and state compounding regulations, which is not the same as an FDA-approved drug. Approval by a provider for any individual is never guaranteed.
What happens if a provider decides the combo is not appropriate for me?
Then it is not prescribed. A provider can decline, request more information, or suggest that only part of what you asked about is appropriate. That is the point of an individual evaluation. Nothing here is a promise that either BPC-157 or the combo will be approved, and some people will not be.
Does the preclinical research mean these will work for me?
No. Preclinical research, meaning animal and cell-culture studies, can suggest a biological mechanism worth studying. It does not prove a specific outcome in humans. Human data for both BPC-157 and TB-500 remains limited, and no clinic can promise or imply a guaranteed result. Individual results vary.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Still deciding between BPC-157 and the combo? Start your private evaluation at TelosRX and let a licensed provider help you sort out what actually fits.